GT Biopharma (GTBP) 10-K 28 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 28, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-40023
Entity Registrant Name	GT BIOPHARMA, INC.
Entity Central Index Key	0000109657
Entity Tax Identification Number	94-1620407
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Marina Blvd.
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	(415)
Local Phone Number	919-4040
Title of 12(b) Security	Common Stock, $.001 Par Value
Trading Symbol	GTBP
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 372.3
Entity Common Stock, Shares Outstanding		32,122,844
Documents Incorporated by Reference	In Part III, portions of the registrant’s 2022
Auditor Name	Weinberg & Company, P.A
Auditor Location	Los Angeles, California
Auditor Firm ID	572

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 8,968	$ 5,297
Short-term investments	23,011
Prepaid expenses and other current assets	190	364
Total current assets	32,169	5,661
Current liabilities
Accounts payable	8,189	2,243
Accrued expenses	1,901	1,296
Accrued interest		4,838
Convertible notes payable (net of discount of $4,519 at December 31, 2020)		26,303
Line of credit	31	31
Derivative liability	138	383
Total current liabilities	10,259	35,094
Stockholders’ equity (deficit)
Common stock, par value $0.001, 750,000,000 shares authorized, 32,061,989 shares and 5,218,122 shares issued and outstanding as of December 31, 2021 and 2020, respectively	32	5
Common stock issuable 327,298 shares at December 31, 2021	1,113
Additional paid in capital	674,348	566,356
Accumulated deficit	(653,584)	(595,797)
Total stockholders’ equity (deficit)	21,910	(29,433)
Total liabilities and stockholders’ equity (deficit)	32,169	5,661
Series C Preferred Stock [Member]
Stockholders’ equity (deficit)
Convertible Preferred stock	1	1
Series J Preferred Stock [Member]
Stockholders’ equity (deficit)
Convertible Preferred stock		$ 2

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Long term convertible debentures discount		$ 4,519
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	15,000,000	15,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	750,000,000	750,000,000
Common Stock, Shares, Issued	32,061,989	5,218,122
Common Stock, Shares, Outstanding	32,061,989	5,218,122
Common Stock Issuable, Shares	327,298
Series C Preferred Stock [Member]
Preferred stock, issued	96,230	96,230
Preferred stock, outstanding	96,230	96,230
Series J Preferred Stock [Member]
Preferred stock, issued	0	2,353,548
Preferred stock, outstanding	0	2,353,548

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues
Operating Expenses:
Research and development	9,591	485
Selling, general and administrative (including $17,234 of stock compensation to officers, directors and employees during the year ended December 31, 2021)	47,924	6,279
Loss from Operations	57,515	6,764
Other (Income) Expense
Interest income	(38)
Interest expense	718	3,003
Change in fair value of derivative liability	(211)	230
Unrealized loss on marketable securities	29
Loss on forbearance agreement		12,598
Loss on legal settlements		5,384
Amortization of debt discount		317
Total Other (Income) Expense	498	21,532
Net Loss	$ (58,013)	$ (28,296)
Net loss per share - basic and diluted	$ (2.06)	$ (6.45)
Weighted average common shares outstanding - basic and diluted	28,155,624	4,385,222

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Officers and Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Share-based Payment Arrangement, Expense	$ 17,234

Consolidated Statements Of Stoc

Consolidated Statements Of Stockholders' Equity (Deficit) - USD ($) shares in Thousands	Preferred Stock [Member]	Common Stock [Member]	Common Shares Issuable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3,000	$ 4,000		$ 548,184,000	$ (567,501,000)	$ (19,310,000)
Beginning balance, shares at Dec. 31, 2019	2,450	4,105
Fair value of amended convertible notes and warrants				8,643,000		8,643,000
Issuance of common and warrants for settlement of litigation				2,246,000		2,246,000
Issuance of common and warrants for settlement of litigation, shares		262
Beneficial conversion feature on convertible notes payable				5,274,000		5,274,000
Common shares issued upon conversion of notes payable		$ 1,000		1,740,000		1,741,000
Common shares issued upon conversion of notes payable, shares		512
Common shares issued upon exercise of warrants
Common shares issued upon exercise of warrants, shares		240
Issuance of common stock for compensation				269,000		269,000
Issuance of common stock for compensation, shares		99
Net loss					(28,296,000)	(28,296,000)
Ending balance, value at Dec. 31, 2020	$ 3,000	$ 5,000		566,356,000	(595,797,000)	(29,433,000)
Ending balance, shares at Dec. 31, 2020	2,450	5,218
Extinguishment of debt discount upon adoption of ASU 2020-06				(4,745,000)	226,000	(4,519,000)
Conversion of Preferred Series J-1 to common stock	$ (2,000)	$ 1,000		1,000
Conversion of Preferred Series J-1 to common stock, shares	(2,354)	692
Common shares issued upon mandatory conversion of notes payable and accrued interest		$ 11	$ 1,113	37,675		38,799
Common shares issued upon mandatory conversion of notes payable and accrued interest, shares		11,086	327
Common shares issued upon exercise of warrants		$ 3,000		16,430,000		16,433,000
Common shares issued upon exercise of warrants, shares		3,074
Issuance of common stock in public offering, net of cost		$ 5,000		24,674,000		24,679,000
Issuance of common stock in public offering, net of cost, shares		4,945
Issuance of common stock for research and development agreement				1,355,000		1,355,000
Issuance of common stock for research and development agreement, shares		190
Issuance of common stock for services		$ 3,000		15,337,000		15,340,000
Issuance of common stock for services, shares		3,082
Equity compensation to officers, board of directors and employees		$ 4,000		17,230,000		17,234,000
Equity compensation to officers and board of directors, shares		3,775
Extinguishment of derivative liability				35,000		35,000
Net loss					(58,013,000)	(58,013,000)
Ending balance, value at Dec. 31, 2021	$ 1,000	$ 32,000	$ 1,113,000	$ 674,348,000	$ (653,584,000)	$ 21,910,000
Ending balance, shares at Dec. 31, 2021	96	32,062	327

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (58,013)	$ (28,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation - consultants and research and development	16,695
Stock based compensation - officers, directors and employees	17,234	269
Convertible notes payable issued for consulting services	720
Amortization of debt discount		317
Convertible notes payable issued and fair value of amended convertible notes payable and warrants as part of forbearance agreements		12,598
Convertible notes payable issued and fair value of common shares and warrants issued as part of legal settlements		5,003
Loss on abandonment of lease		60
Change in fair value of derivative liability	(211)	230
Unrealized loss on marketable securities	29
Issuance of warrants accounted as derivative liability		153
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses	174	242
Increase (decrease) in accounts payable and accrued expenses	7,077	(838)
Increase in accrued interest	689	3,000
Net Cash Used in Operating Activities	(15,606)	(7,262)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(23,040)
Net Cash Used in Investing Activities	(23,040)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants	16,433
Proceeds from issuance of common stock	24,679
Proceeds from issuance of convertible notes payable	1,205	12,531
Net Cash Provided by Financing Activities	42,317	12,531
Net Increase in Cash	3,671	5,269
Cash at Beginning of Period	5,297	28
Cash at End of Period	8,968	5,297
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest
Income taxes paid
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06	4,745
Beneficial conversion feature of notes payable issued for cash		4,745
Common stock issued upon conversion of notes payable and accrued interest	38,799	1,741
Accounts payable reclassified to convertible notes	525
Extinguishment of derivative liability	35
Conversion of Series J Preferred Stock to Common Stock	2
Convertible notes payable issued for consulting services		360
Reclassification of lease liability to accrued expenses		$ 58

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 – Organization and Operations In 1965, the corporate predecessor of GT Biopharma Inc. (the Company), Diagnostic Data, Inc., was incorporated in the State of California. Diagnostic Data changed its incorporation to the State of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. In July 2017, the Company changed its name to GT Biopharma, Inc. The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE ® ® ® ® ®

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation. Liquidity The accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December 31, 2021, the Company recorded a net loss of $ 58.0 33.9 15.6 32.0 22.9 32.0 During the year ended December 31, 2021 the Company raised $ 24.7 16.4 1.2 Historically, the Company has financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. Reclassification of Prior Year Presentation Certain prior year amounts due to the resolution of non-controlling interest in net loss have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. COVID-19 In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the normal operations of many businesses. This outbreak could decrease spending, adversely affect demand for the Company’s products, and harm the Company’s business and results of operations. During the year ended December 31, 2021, the Company believes the COVID-19 pandemic did impact its operating results. However, the Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition or liquidity. The Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including a temporary closure of its corporate office and having team members work remotely. Most vendors have transitioned to electronic submission of invoices and payments. Accounting Estimates The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities, valuation of notes payable, assumptions used in deriving the fair value of derivative liabilities, share-based compensation and beneficial conversion feature of notes payable, and valuation of deferred tax assets. Actual results could differ from those estimates. Stock-Based Compensation The Company accounts for share-based awards to employees and nonemployees and consultants in accordance with the provisions of Accounting Standards Codification (“ASC”) 718, Compensation-Stock Compensation. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published federal funds rates. Fair Value of Financial Instruments Financial Accounting Standards Board (“ FASB”) ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The three levels of the fair value hierarchy are as follows: Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amount of the Company’s derivative liability of $ 0.1 The carrying amounts of the Company’s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued expenses, and notes payable, approximate their fair values because of the short maturity of these instruments. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on subsequent valuation dates. Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Research and Development Costs Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products comprise research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Leases The Company leases our corporate office space under a lease agreement with monthly payments over a period of 12 months. Pursuant to ASC 842, Leases 4,500 commencement date of January 1, 2022 and maturing on June 30, 2024 Net Loss Per Share Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of convertible notes, stock issuable to the exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. The following shares were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities 2021 2020 December 31, 2021 2020 A. Warrants to purchase common stock 2,337,274 221,041 B. Convertible notes payable - 9,065,262 C. Convertible Series J Preferred stock - 692,220 D. Convertible Series C Preferred stock - 7 E. Options to purchase common stock 302,500 - Total anti-dilutive securities 2,639,774 9,978,530 Concentration Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $ 250,000 The Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further information. Segments The Company determined its reporting units in accordance with ASC 280, “ Segment Reporting Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity 4.5 million (see Note 5). In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (the “SEC”) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 - Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): Schedule of Estimated Fair Value of Financial Instrument December 31, 2021 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 8,968 (8,189) $ — $ — $ 8,968 Short-term investments 23,040 — (29 ) 23,011 $ 32,008 $ — $ (29 ) $ 31,979 December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,297 $ — $ — $ 5,297 Short-term investments — — — — $ 5,297 $ — $ — $ 5,297 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands): Schedule of Fair Value Hierarchy Financial Assets Fair Value Level 1 Level 2 Level 3 December 31, 2021 Fair Value Level 1 Level 2 Level 3 Money market funds $ 5,484 $ 5,484 $ — $ — Corporate notes and commercial paper 23,011 — 23,011 — Total financial assets $ 28,495 $ 5,484 $ 23,011 $ —

Accounts Payable

Accounts Payable	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable	Note 4 – Accounts Payable Accounts payable consisted of the following (in thousands): Schedule of Accounts Payable December 31, 2021 December 31, 2020 Accounts payable to a third-party manufacturer $ 6,335 $ - Other accounts payable 1,854 2,243 Total accounts payable $ 8,189 $ 2,243 The Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates. As of December 31, 2021 the Company was indebted $ 6.3 million of accounts payable to this vendor.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 5 – Convertible Notes Payable Convertible notes payable consisted of the following (in thousands): Schedule of Convertible Notes Payable December 31, 2021 December 31, 2020 A. Notes payable issued for cash $ - $ 24,085 B. Notes payable issued for settlement agreements - 2,528 C. Notes payable issued for forbearance agreements - 3,849 D. Notes payable issued for consulting services - 360 - 30,822 Less unamortized debt discount - (4,519 ) Convertible notes, net of discount $ - $ 26,303 A. Notes Payable Issued for Cash As part of the Company’s financing activities, the Company issued convertible notes payable in exchange for cash. These notes payable were unsecured, bearing interest at a rate of 10 % per annum, matured from nine months up to one year from the date of issuance, and were convertible to common stock at an average conversion rate of $ 3.40 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 4.99 %) and standard anti-dilution provisions. As of December 31, 2020, the outstanding balance of these notes amounted to $ 24.1 million . In January 2021, the Company issued similar notes payable in exchange for cash of $ 1.2 million . On February 16, 2021, in accordance with the note agreements upon completion of the equity offering discussed in Note 8, these notes were mandatorily converted at a conversion rate of $ 3.40 per share into 7,438,235 shares of the Company’s common stock. B. Notes Payable Issued for Settlement Agreements In fiscal 2019 and 2020, the Company issued its convertible notes payable to resolve claims and disputes pertaining to certain debt and equity instruments issued by the Company in prior years. The notes were unsecured, bearing interest at a rate of 10 %, matured from nine months up to one year from the date of issuance, and were convertible to common stock at a conversion rate of $ 3.40 per share, as adjusted, subject to certain beneficial ownership limitations (with a maximum ownership limit of 4.99 %) and standard anti-dilution provisions. As of December 31, 2020, outstanding balance of these notes payable for settlement agreements amounted to $ 2.5 million . On February 16, 2021 in accordance with the note agreements upon completion of the equity offering discussed in Note 8, these notes were mandatorily converted at a conversion rate of $ 3.40 per share into 743,529 shares of the Company’s common stock. C. Notes Payable Issued for Forbearance Agreements On June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the “Forbearance Agreements”) with the holders of $ 13.2 million aggregate principal amount of the Convertible Notes (the “Default Notes”), which were in default. Pursuant to the Forbearance Agreements, the holders of the Default Notes agreed to forbear from exercising their rights and remedies under the Default Notes (including declaring such Default Notes (together with any default amounts and accrued and unpaid interest) immediately due and payable) until the earlier of (i) the date that the Company completes a future financing in the amount of $ 15 million and, in connection therewith, commences listing on NASDAQ (collectively, the “New Financing”) or (ii) January 31, 2021 (the “Termination Date”). As of December 31, 2020, outstanding balance of the notes payable amounted to $ 3.8 . On February 16, 2021 in accordance with the note agreements upon completion of the equity offering discussed in Note 8, these notes were mandatorily converted at a conversion rate of $ 3.40 per share into 1,132,059 shares of the Company’s common stock. D. Notes Payable issued for Consulting Agreements In prior years, the Company issued its convertible notes payable in exchange for consulting services. These notes payable were unsecured, bearing interest at a rate of 10 % per annum, matured from nine months up to one year from the date of issuance, and were convertible to common stock at an average conversion rate of $ 3.40 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 4.99% ) and standard anti-dilution provisions. As of December 31, 2020, outstanding balance of these notes payable amounted to $ 0.4 million . In January 2021, the Company issued similar notes payable of $ 0.7 in exchange for consulting services. In addition, the Company also issued a note payable of $ 0.5 in exchange for the cancellation of an unpaid consulting fee that was recorded as part of accrued expenses as of December 31, 2020. On February 16, 2021 in accordance with the note agreements upon completion of the equity offering discussed in Note 8, these notes in the aggregate amount of $ 1.6 million were mandatorily converted at a conversion rate of $ 3.40 per share into 472,059 shares of the Company’s common stock. As of December 31, 2020, the Company accrued interest of $ 4.8 million related to these convertible notes payable. During the period ended December 31, 2021, the Company accrued interest of $ 0.7 million . As a result of the mandatory conversion of the Company’s notes payable, on February 16, 2021, total accrued interest amounting to $ 5.5 million was converted to 1,627,440 shares of common stock. As a result, total notes payable of $ 33.3 million and accrued interest of $ 5.5 million for a total of $ 38.8 million were mandatorily converted to 11,413,322 shares of common stock of which 327,298 Adoption of ASU 2020-06 In fiscal 2020, the Company recorded a note/debt discount of $ 4.7 to account for the beneficial conversion feature that existed on the date of issuance for the above convertible notes payable. The debt discount is being amortized to interest expense over the term of the corresponding convertible notes payable. At December 31, 2020, the Company had recorded an unamortized note/debt discount of $ 4.5 . On January 1, 2021 the Company chose to adopt Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity As a result of the adoption of ASU 2020-06, the Company extinguished the previously recorded debt discount of $ 4.7 by charging the opening additional paid in capital at January 1, 2021. In addition, the Company also adjusted accumulated deficit to account for the derecognition of the $ 0.2 interest expense due to the amortization of the debt discount that was recorded in fiscal 2020. As a result of these adjustments, the unamortized debt discount of $ 4.5 was extinguished during the year ended December 31, 2021.

Line of Credit

Line of Credit	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Line of Credit	Note 6 – Line of Credit On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $ 0.3 strategic equity investment in the Company and agreed to make a $ 0.8 purchase order line of credit facility available to the Company. The principal balance outstanding under the line of credit, which bears interest at the rate of prime plus 2 % per annum, amounted to $ 31,000 as of December 31, 2021 and 2020, respectively.

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2021
Derivative Liability
Derivative Liability	Note 7 – Derivative Liability Under authoritative guidance used by the FASB on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, instruments that do not have fixed settlement provisions are deemed to be derivative instruments. The Company has issued certain warrants t hat included a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder. As a result, the warrants are classified as liabilities and are bifurcated from the debt host and accounted for as a derivative liability in accordance with ASC 815 and will be re-measured at the end of every reporting period with the change in value reported in the statement of operations. The derivative liabilities were valued using a Binomial pricing model with the following average assumptions: Schedule of Derivative Liabilities Assumptions December 31, 2021 December 31, 2020 Risk-free interest rate 1.26 % 0.36 % Expected volatility 129 % 135 % Expected life (in years) 3.6 4.60 Expected dividend yield - - Fair Value Warrants $ 138,000 $ 383,000 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by the remaining contractual life of the derivative instrument. For derivative instruments that already matured, the Company used the estimated life. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. During 2021, 2,826 0.03 million 0.21 and a loss of $ 0.23 million for the years ended December 31, 2021 and 2020, respectively, to account for the change in fair value of the derivative liability.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity (Deficit)	Note 8 – Stockholders’ Equity (Deficit) At December 31, 2021, the Company had an authorized capital of 750,000,000 shares of common stock, par value $ 0.001 , and 15,000,000 shares of preferred stock par value $ 0.01 . On February 10, 2021, the Company effectuated a 1:17 reverse stock split of the Company’s issued and outstanding shares of common stock and all fractional shares were rounded up. All share and per share amounts in the accompanying consolidated financial statements have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. Common Stock Common Stock Issuable As a result of the mandatory conversion of the notes payable and accrued interest in the aggregate of $ 38.8 on February 16, 2021, the Company was obligated to issue a total of 11,413,322 shares of common stock to the respective noteholders. As of December 31, 2021, the Company had issued 11,085,703 shares of common stock or approximately 97.1 % or $ 37.7 million of the converted notes payable and accrued interest to the respective noteholders. With regards to the remaining 327,298 unissued shares of common stock or $ 1.1 million of the converted notes payable and accrued interest, the Company is in the process of obtaining the necessary supporting documentation from the respective noteholders which will then be provided to the Company’s stock transfer agent as a requirement for the issuance of the common stock certificate (Note 5). For financial reporting purposes, the Company reported $ 1.1 million as common stock issuable in the accompanying statements of stockholders’ equity to account for the estimated balance of the converted notes payable and accrued interest that the Company has not yet issued the corresponding common stock. Issuance of Common Stock in public offering On February 16, 2021, the Company completed a public offering of 4,945,000 shares of common stock for net proceeds of $ 24.7 , after deducting underwriting discounts, commissions and other direct offering expenses. As part of the offering, the Company also granted these investors, warrants to purchase 5,192,250 shares of common stock. The warrants are fully vested, exercisable at $ 5.50 per share and will expire in five years . As a result of the completion of the public offering and the successful listing of its shares of common stock on the Nasdaq Capital Market, convertible notes with an aggregate principal amount of $ 33.3 million and accrued interest of $ 5.5 million mandatorily converted at its stated conversion rate of $ 3.40 per share into 11,413,322 shares of the Company’s common stock (see Note 5). Issuance of Common Stock for services - consultants As part of consulting agreements with certain consultants, the Company agreed to grant these consultants common stock equal to 1 3 On February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As a result of this offering, the Company agreed to issue to these consultants 2,850,090 shares of common stock with a grant date fair value of $ 10.7 million, of which 1,934,817 shares of common stock vested immediately while the remaining 915,273 , shares of common stock vests over two years . Pursuant to current accounting guidelines, as the grant of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common stock on the respective date of the agreement, and then such award is being recorded as compensation expense based upon the vesting term of the grant. During the period ended December 31, 2021, pursuant to the vesting terms of the agreements, the Company recorded stock compensation expense of $ 9.0 million related to these consultants. In addition, the Company also issued 1,060,853 shares of common stock with a grant date fair value of $ 6.8 million to other consultants for service rendered that will vest over a period of 24 278,058 15.3 million in stock compensation expense based upon the vesting of common stock granted to consultants. At December 31, 2021, there are 550,479 unvested shares of common stock with a grant date fair value of $ 2.2 which will be recognized as stock compensation in future periods. Issuance of Common Stock for research and development agreement During the year ended December 31, 2021, the Company issued 189,753 shares of common stock for a research and development agreement valued at $ 1.4 million . The common shares were valued on the market price at the date of grant. Issuance of Common Stock upon exercise of warrants During the year ended December 31, 2021, the Company issued 3,076,017 shares of common stock upon the exercise of warrants resulting in cash proceeds of $ 16.4 . During the year ended December 31, 2020, the Company issued 239,706 Issuance of Common Stock upon conversion of notes payable During the year ended December 31, 2020, the Company issued 511,879 1.7 million Issuance of Common Stock for legal settlements During the year ended December 31, 2020, the Company issued 262,353 2.2 million As a result of all common stock issuances, the Company had 32,061,989 shares and 5,218,122 shares of common stock issued and outstanding at December 31, 2021 and December 31, 2020, respectively. Preferred Stock A. Series J Preferred Stock At December 31, 2021 and December 31, 2020, respectively, there were 0 2,353,548 Shares of the Series J-1 Preferred Stock were convertible at any time, at the option of the holders, into shares of the Company’s common stock at an effective conversion price of $ 3.40 per share, subject to adjustment for, among other things, stock dividends, stock splits, combinations, reclassifications of our capital stock and mergers or consolidations, and subject to a beneficial ownership limitation which prohibits conversion if such conversion would result in the holder (together with its affiliates) being the beneficial owner of in excess of 9.99 % of the Company’s common stock. Shares of the Series J-1 Preferred Stock had the same voting rights as shares of the Company’s common stock, with the holders of the Series J-1 Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation described above, together with the holders of the Company’s common stock on all matters presented to the Company’s stockholders. The Series J-1 Preferred Stock are not entitled to any dividends (unless specifically declared by the Board), but would participate on an as-converted-to-common-stock basis in any dividends to the holders of the Company’s common stock. In the event of the Company’s dissolution, liquidation or winding up, the holders of the Series J-1 Preferred Stock would be on parity with the holders of the Company’s common stock and would participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company’s common stock. As a result of the completion of the public offering and the successful listing of the Company’s shares of common stock on the Nasdaq Capital Market, in February 2021, all outstanding Series J shares were mandatorily converted to 692,220 B. Series C Preferred Stock At both December 31, 2021 and December 31, 2020, there were 96,230 shares of series C preferred stock, par value $ 0.01 As a result of stock splits in previous years, 96,230 shares of Series C Preferred Stock are not convertible. Shares of Series C Preferred Stock have no voting rights. Similarly, as there are no conversion rights, in the event of liquidation, the holders of the Series C Preferred Stock shall not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not entitled to any dividends if and when declared by the Company’s board of directors (the “Board”). No dividends to holders of the Series C Preferred Stock were issued or unpaid through December 31, 2021 and 2020. C. Series K Preferred Stock On February 16, 2021, the Board designated 115,000 .01 Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company’s common stock at an effective conversion rate of 100 shares of common stock for each share of Series K Preferred Stock. Shares of the Series K Preferred Stock have the same voting rights a shares of the Company’s common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders of the Company’s common stock on all matters presented to the Company’s stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board), but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Company’s common stock. In the event of the Company’s dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company’s common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company’s common stock. As of December 31, 2021, there were no Warrants and Options Common Stock Warrants Stock warrant transactions for the years ended December 31, 2021 and 2020 were as follows: Schedule of Warrant activity Number of Warrants Weighted-Average Exercise Price Warrants outstanding at December 31, 2019 106,650 $ 3.40 Granted 382,353 3.40 Forfeited/canceled (28,256 ) 3.40 Exercised (239,706 ) - Warrants outstanding at December 31, 2020 221,041 3.40 Granted 5,192,250 5.50 Forfeited/canceled - - Exercised (3,076,017 ) 5.50 Warrants outstanding at December 31, 2021 2,337,274 $ 5.30 Warrants exercisable at December 31, 2021 2,337,274 $ 5.30 On February 16, 2021, as part of the Company’s public offering, the Company issued warrants to investors to purchase up to an aggregate of 5,192,250 5.50 five years During the year ended December 31, 2021, the Company issued 3,076,017 16.4 On July 28, 2020, the Company issued a warrant to purchase up to an aggregate of 58,824 shares of common stock at an exercise price of $ 3.40 per share, subject to adjustment in certain circumstances with a fair value of $ 0.2 million. The warrant expires on July 28, 2025. The warrant was issued as compensation for certain services provided to the Company. In July 2020, pursuant to the Settlement Agreement, the Company issued pre-funded warrants to purchase up to an aggregate of 323,529 shares of common stock (the “Settlement Warrants”) at an exercise price of $ 3.40 per share, subject to adjustment in certain circumstances and will expire on June 19, 2025 As of December 31, 2021, all issued and outstanding warrants are fully vested and the intrinsic value of these warrants was $ 0 Common Stock Options Stock option transactions for the year ended December 31, 2021 (there were no transactions in 2020): Schedule of Options Activity Number of Options Weighted-Average Exercise Price Options outstanding at December 31, 2020 - - Granted 302,500 3.05 Forfeited/canceled - - Exercised - - Options outstanding at December 31, 2021 302,500 $ 3.05 Options exercisable at December 31, 2021 93,825 $ 3.05 On December 31, 2021, the Company granted two employees a total of 302,500 3.05 10 years 808,000 2.67 5.5 129.0% 1.26% 0% 250,700 There was no

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies 1. Litigation The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, the Company records accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being handled in, the normal course of business. a. On August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica Courthouse, Unlimited Civil Division by Jeffrey Lion and by Daniel Vallera, as individuals. The complaint was filed against GT Biopharma, Inc. and its subsidiary Oxis Biotech, Inc. The Plaintiffs allege breach of a license agreement between the Plaintiffs and the Company entered into on or about September 3, 2015. The Company filed an answer to the complaint denying many allegations and asserting affirmative defenses. The Company reached a settlement of the case and paid on March 4, 2022, $ 425,000 in full and final settlement of the claims (see Note 14). This amount was fully accrued at December 31, 2021 and 2020, respectively. b. On March 3, 2021, a complaint was filed by Sheffield Properties in the superior Court of California, County of Ventura. The litigation arose from a commercial lease entered into by GT Biopharma, Inc. for office space in Westlake Village in California. In July, 2021 the Company entered into settlement agreement with Sheffield Properties and the payment in the settlement amount of $ 0.1 million was made on August 6, 2021. 2. Significant Agreements Research and Development Agreements The Company is a party to a Scientific Research Agreement with the Regents of the University of Minnesota, effective June 16, 2021. This scientific research agreement has three major goals: (1) support the Company’s TriKE ® ® ® ® ® ® The University of Minnesota shall use reasonable efforts to complete the project for a fixed sum of $ 2.1 million 541,527 191,527 191,527 192,470 On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At December 31, 2021, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $ 13.0 7.5 5.5 Patent and License Agreements 2016 Exclusive Patent License Agreement The Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (“UofMN”), to further develop and commercialize cancer therapies using TriKE ® ® ® 0.2 0.1 million 4% 0.25 million 5.0 million. 3.1 million 1.0 million 250 5.0 million 500 2021 Patent License Agreement On March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE ® 20,000 5,000 2.5% 5% 0.25 million 2.0 million 3.1 million 1.0 million 250 5.0 million 500 Office Lease Agreement On November 19, 2021 the Company entered into a sublease with Aimmune Therapeutics, Inc. for 4,500 commencement date of January 1, 2022 and maturing on June 30, 2024 Schedule Of Future Minimum Lease Payments Year ending Amount 2022 $ 113 2023 117 2026 and thereafter 60 Total $ 290 3. Employee Compensation The following table summarizes the Company’s future financial commitment to certain employees pursuant to their respective employment agreements (in thousands): Schedule of Company’s Future Financial Commitment Year ending Amount 2022 $ 1,756 2023 1,293 2024 1,012 2025 377 2026 and thereafter - Total $ 4,438

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax	Note 10 – Income Tax The Company did not record any income tax provision for the years ended December 31, 2021 and 2020 due to the Company’s net losses. The Company files income tax returns in the United States (“Federal”) and California, Minnesota and Massachusetts (“State”) jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception. At December 31, 2021, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of approximately $ 195 million. These carry forwards will begin to expire in the year ending December 31, 2030 , subject to IRS limitations, including change in ownership. The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. At December 31, 2021 and 2020, based on the weight of available evidence, including cumulative losses in recent years and expectations of future taxable income, the Company determined that it was more likely than not that its deferred tax assets would not be realized. Accordingly, the Company has recorded a valuation allowance for 100 Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant components of net deferred income tax assets for the Company are (in thousands): Schedule of Net Deferred Income Tax Assets December 31, 2021 2020 Deferred tax assets: Federal net operating loss carryforward $ 58,167 $ 39,340 Stock based compensation and other items 7,622 4,779 Intellectual property 62,055 58,504 Patent amortization 4 4 Deferred tax assets before valuation 127,848 102,627 Valuation allowance (127,848 ) (102,627 ) Net deferred income tax assets $ - $ - Generally accepted accounting principles requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s history of operating losses, management has provided a valuation allowance equal to its net deferred tax assets. A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax provision is as follows for the year ended: Schedule of Income Tax Provision December 31, 2021 2020 Federal statutory income tax rate 21 % 21 % State tax, net of federal benefit 9 % 7 % Change in valuation allowance on net operating loss carryforwards ( 30 ) % ( 28 )% Effective income tax rate 0 % 0 %

Related Party Transaction

Related Party Transaction	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transaction	Note 11 – Related Party Transaction During the year ended December 31, 2020, the Company recorded consulting expense of $ 1.1 million for services rendered by a consultant who was also an owner of approximately 10 % of the Company’s issued and outstanding common stock. In addition, the Company also issued a note payable to this consultant of $ 0.5 million in exchange for the cancellation of unpaid consulting fees of $ 0.5 million that was recorded as part of accrued expenses at December 31, 2020. There was no similar consulting expense incurred during the period ended December 31, 2021.

Equity Compensation to Officers

Equity Compensation to Officers, Board of Directors and Employees	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Equity Compensation to Officers, Board of Directors and Employees	Note 12 – Equity Compensation to Officers, Board of Directors and Employees As part of employment agreements with its former CEO and its former CFO (“Officers”), the Officers received a fully vested stock grant equal to aggregate of 10 % and 1.5 % of the fully diluted shares of common stock of the Company (calculated with the inclusion of the current stock holdings of the CEO) upon conversion of options, warrants and Convertible Notes in association with a national markets qualified financing as consideration for entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets qualified financing). In addition, the Company also granted similar equity compensation to members of the Company’s Board of Directors wherein these directors received stock grant equal to 1 % and 1.25 % of the fully diluted shares of common stock of the Company. Pursuant to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining 67% will vest over a period of two years . On February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market (see Note 8). As such, 4,379,407 shares of its common stock were granted to these Officers and directors which had a fair value of $ 18.6 million . Since the grant of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common stock on the respective date of the agreement, and such awards were recorded as compensation expense as the milestone or performance condition is met and in accordance with its vesting terms. The Company recognized stock compensation expense of $17.2 million which is comprised of the issuance of 4,053,024 shares of common stock and the vesting of 93,825 278,058 338,883 unvested shares of common stock was $1.7 million and will be recognized as stock compensation expense in future periods.

Internal Control Considerations

Internal Control Considerations	12 Months Ended
	Dec. 31, 2021
Internal Control Considerations
Internal Control Considerations	Note 13 – Internal Control Considerations Management has determined that inadequate and/or ineffective internal controls over financial reporting resulted in unauthorized transactions involving the Company’s assets and common stock. Following the termination of Anthony Cataldo, the Company’s former Chief Executive Officer, and Michael Handelman, the Company’s former Chief Financial Officer, management determined that in July 2021, Mr. Cataldo obtained a short-term advance from the Company in the amount of approximately $ 2.6 187,500 The Company is considering its course of action and potential recourse it may have against these former officers. The Company has taken measures to mitigate the issues identified and implement a functional system of internal controls over financial reporting. Specifically, the Company has engaged a forensic accountant to review the Company’s bank records, transactions with affiliates and/or related parties, expense reimbursement practices and vendor payment practices. That review is ongoing. In addition, the Company’s Board of Directors previously designated a Special Committee in August 2021 charged with, among other duties, evaluating the current compliance, compensation, operations and personnel of the Company, and determining actions appropriate to address any deficiencies or inefficiencies identified through such evaluation.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On March 3, 2022, the Company settled a case filed by Jeffrey Lions and Daniel Vallera and paid $ 0.4 million in full and final settlement (see Note 9). The Company has entered into a sublease with Aimmune Therapeutics, Inc. for 4,500 commencement date of January 1, 2022 and maturing on June 30, 2024 On February 11, 2022, 60,855

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity	Liquidity The accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December 31, 2021, the Company recorded a net loss of $ 58.0 33.9 15.6 32.0 22.9 32.0 During the year ended December 31, 2021 the Company raised $ 24.7 16.4 1.2 Historically, the Company has financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts due to the resolution of non-controlling interest in net loss have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
COVID-19	COVID-19 In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the normal operations of many businesses. This outbreak could decrease spending, adversely affect demand for the Company’s products, and harm the Company’s business and results of operations. During the year ended December 31, 2021, the Company believes the COVID-19 pandemic did impact its operating results. However, the Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition or liquidity. The Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including a temporary closure of its corporate office and having team members work remotely. Most vendors have transitioned to electronic submission of invoices and payments.
Accounting Estimates	Accounting Estimates The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities, valuation of notes payable, assumptions used in deriving the fair value of derivative liabilities, share-based compensation and beneficial conversion feature of notes payable, and valuation of deferred tax assets. Actual results could differ from those estimates.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share-based awards to employees and nonemployees and consultants in accordance with the provisions of Accounting Standards Codification (“ASC”) 718, Compensation-Stock Compensation. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published federal funds rates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Accounting Standards Board (“ FASB”) ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The three levels of the fair value hierarchy are as follows: Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amount of the Company’s derivative liability of $ 0.1 The carrying amounts of the Company’s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued expenses, and notes payable, approximate their fair values because of the short maturity of these instruments.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on subsequent valuation dates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Research and Development Costs	Research and Development Costs Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products comprise research and development expenses. Purchased materials that do not have an alternative future use are also expensed.
Leases	Leases The Company leases our corporate office space under a lease agreement with monthly payments over a period of 12 months. Pursuant to ASC 842, Leases 4,500 commencement date of January 1, 2022 and maturing on June 30, 2024
Net Loss Per Share	Net Loss Per Share Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of convertible notes, stock issuable to the exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. The following shares were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities 2021 2020 December 31, 2021 2020 A. Warrants to purchase common stock 2,337,274 221,041 B. Convertible notes payable - 9,065,262 C. Convertible Series J Preferred stock - 692,220 D. Convertible Series C Preferred stock - 7 E. Options to purchase common stock 302,500 - Total anti-dilutive securities 2,639,774 9,978,530
Concentration	Concentration Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $ 250,000 The Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further information.
Segments	Segments The Company determined its reporting units in accordance with ASC 280, “ Segment Reporting Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity 4.5 million (see Note 5). In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (the “SEC”) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities	The following shares were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities 2021 2020 December 31, 2021 2020 A. Warrants to purchase common stock 2,337,274 221,041 B. Convertible notes payable - 9,065,262 C. Convertible Series J Preferred stock - 692,220 D. Convertible Series C Preferred stock - 7 E. Options to purchase common stock 302,500 - Total anti-dilutive securities 2,639,774 9,978,530

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Value of Financial Instrument	The estimated fair values of financial instruments outstanding were (in thousands): Schedule of Estimated Fair Value of Financial Instrument December 31, 2021 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 8,968 (8,189) $ — $ — $ 8,968 Short-term investments 23,040 — (29 ) 23,011 $ 32,008 $ — $ (29 ) $ 31,979 December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,297 $ — $ — $ 5,297 Short-term investments — — — — $ 5,297 $ — $ — $ 5,297
Schedule of Fair Value Hierarchy Financial Assets	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands): Schedule of Fair Value Hierarchy Financial Assets Fair Value Level 1 Level 2 Level 3 December 31, 2021 Fair Value Level 1 Level 2 Level 3 Money market funds $ 5,484 $ 5,484 $ — $ — Corporate notes and commercial paper 23,011 — 23,011 — Total financial assets $ 28,495 $ 5,484 $ 23,011 $ —

Accounts Payable (Tables)

Accounts Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable	Accounts payable consisted of the following (in thousands): Schedule of Accounts Payable December 31, 2021 December 31, 2020 Accounts payable to a third-party manufacturer $ 6,335 $ - Other accounts payable 1,854 2,243 Total accounts payable $ 8,189 $ 2,243

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consisted of the following (in thousands): Schedule of Convertible Notes Payable December 31, 2021 December 31, 2020 A. Notes payable issued for cash $ - $ 24,085 B. Notes payable issued for settlement agreements - 2,528 C. Notes payable issued for forbearance agreements - 3,849 D. Notes payable issued for consulting services - 360 - 30,822 Less unamortized debt discount - (4,519 ) Convertible notes, net of discount $ - $ 26,303

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Liability
Schedule of Derivative Liabilities Assumptions	The derivative liabilities were valued using a Binomial pricing model with the following average assumptions: Schedule of Derivative Liabilities Assumptions December 31, 2021 December 31, 2020 Risk-free interest rate 1.26 % 0.36 % Expected volatility 129 % 135 % Expected life (in years) 3.6 4.60 Expected dividend yield - - Fair Value Warrants $ 138,000 $ 383,000

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Warrant activity	Stock warrant transactions for the years ended December 31, 2021 and 2020 were as follows: Schedule of Warrant activity Number of Warrants Weighted-Average Exercise Price Warrants outstanding at December 31, 2019 106,650 $ 3.40 Granted 382,353 3.40 Forfeited/canceled (28,256 ) 3.40 Exercised (239,706 ) - Warrants outstanding at December 31, 2020 221,041 3.40 Granted 5,192,250 5.50 Forfeited/canceled - - Exercised (3,076,017 ) 5.50 Warrants outstanding at December 31, 2021 2,337,274 $ 5.30 Warrants exercisable at December 31, 2021 2,337,274 $ 5.30
Schedule of Options Activity	Stock option transactions for the year ended December 31, 2021 (there were no transactions in 2020): Schedule of Options Activity Number of Options Weighted-Average Exercise Price Options outstanding at December 31, 2020 - - Granted 302,500 3.05 Forfeited/canceled - - Exercised - - Options outstanding at December 31, 2021 302,500 $ 3.05 Options exercisable at December 31, 2021 93,825 $ 3.05

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule Of Future Minimum Lease Payments
Schedule of Company’s Future Financial Commitment	The following table summarizes the Company’s future financial commitment to certain employees pursuant to their respective employment agreements (in thousands): Schedule of Company’s Future Financial Commitment Year ending Amount 2022 $ 1,756 2023 1,293 2024 1,012 2025 377 2026 and thereafter - Total $ 4,438

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Net Deferred Income Tax Assets	Schedule of Net Deferred Income Tax Assets December 31, 2021 2020 Deferred tax assets: Federal net operating loss carryforward $ 58,167 $ 39,340 Stock based compensation and other items 7,622 4,779 Intellectual property 62,055 58,504 Patent amortization 4 4 Deferred tax assets before valuation 127,848 102,627 Valuation allowance (127,848 ) (102,627 ) Net deferred income tax assets $ - $ -
Schedule of Income Tax Provision	A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax provision is as follows for the year ended: Schedule of Income Tax Provision December 31, 2021 2020 Federal statutory income tax rate 21 % 21 % State tax, net of federal benefit 9 % 7 % Change in valuation allowance on net operating loss carryforwards ( 30 ) % ( 28 )% Effective income tax rate 0 % 0 %

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	2,639,774	9,978,530
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	2,337,274	221,041
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities		9,065,262
Convertible Series J Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities		692,220
Convertible Series C Preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities		7
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	302,500

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Nov. 19, 2021ft²	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Defined Benefit Plan Disclosure [Line Items]
Net loss		$ 58,013,000	$ 28,296,000
Non-cash stock compensation		33,900,000
Cash in Operating activities		15,606,000	7,262,000
Cash and short-term investments		32,000,000
Working capital and stockholders' equity		22,900,000
Cash and investments		32,000,000
Proceeds from issuance of common stock		24,679,000
Proceeds from exercise of warrants		16,433,000
Proceeds from issuance of convertible notes		1,200,000
Derivative liability		138,000	$ 383,000
FDIC amount		250,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		4,500,000
Aimmune Therapeutics Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Office space | ft²	4,500
Sublease maturity, description	commencement date of January 1, 2022 and maturing on June 30, 2024
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability		$ 100,000

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Cost	$ 32,008	$ 5,297
Unrealized gains
Unrealized losses	(29)
Fair value	31,979	5,297
Accounts Payable [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
[custom:AvailableForSalesDebtSecuritiesAmortizedCostBasis-0]	(8,189)
Cash and Cash Equivalents [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Cost	8,968	5,297
Unrealized gains
Unrealized losses
Fair value	8,968	5,297
Short-Term Investments [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Cost	23,040
Unrealized gains
Unrealized losses	(29)
Fair value	$ 23,011

Schedule of Fair Value Hierarch

Schedule of Fair Value Hierarchy Financial Assets (Details) $ in Thousands	Dec. 31, 2021USD ($)
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	$ 28,495
Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	5,484
Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	23,011
Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets
Money Market Funds [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	5,484
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	5,484
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets
Corporate Notes and Commercial Paper [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	23,011
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets	23,011
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total financial assets

Schedule of Accounts Payable (D

Schedule of Accounts Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts payable to a third-party manufacturer	$ 6,335
Other accounts payable	1,854	2,243
Total accounts payable	$ 8,189	$ 2,243

Accounts Payable (Details Narra

Accounts Payable (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Accounts Payable, Current	$ 8,189	$ 2,243
Third Party Manufacturer [Member]
Defined Benefit Plan Disclosure [Line Items]
Accounts Payable, Current	$ 6,300

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Convertible notes payable		$ 30,822
Less unamortized debt discount		(4,519)
Convertible notes payable		26,303
Notes Payables Issued For Cash [Member]
Short-term Debt [Line Items]
Convertible notes payable		24,085
Notes Payable Issued For Settlement Agreements [Member]
Short-term Debt [Line Items]
Convertible notes payable		2,528
Notes Payable Issued For Forbearance Agreements [Member]
Short-term Debt [Line Items]
Convertible notes payable		3,849
Notes Payable Issued For Consulting Services [Member]
Short-term Debt [Line Items]
Convertible notes payable		$ 360

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Feb. 16, 2021	Jan. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 23, 2020
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 38,800
Debt Conversion, Converted Instrument, Shares Issued	11,413,322
Accrued Liabilities, Current			$ 1,901	$ 1,296
Debt Instrument, Unamortized Discount				4,519
Common Stock [Member]
Short-term Debt [Line Items]
Common Stock, Shares Subscribed but Unissued			327,298
Notes Payables Issued For Cash [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate During Period			10.00%
Debt Instrument, Convertible, Conversion Price			$ 3.40
[custom:BeneficialOwnershipLimit-0]			4.99%
Notes Payable, Current				24,100
Debt Conversion, Converted Instrument, Amount		$ 1,200
Notes Payables Issued For Cash [Member] | January 2021 [Member]
Short-term Debt [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.40
Debt Conversion, Converted Instrument, Shares Issued	7,438,235
Notes Payable Issued For Settlement Agreements [Member] | Fiscal 2019 and 2020 [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate During Period			10.00%
Debt Instrument, Convertible, Conversion Price	$ 3.40		$ 3.40
[custom:BeneficialOwnershipLimit-0]			4.99%
Notes Payable, Current				2,500
Debt Conversion, Converted Instrument, Shares Issued	743,529
Notes Payable Issued For Forbearance Agreements [Member]
Short-term Debt [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.40
Notes Payable, Current				3,800
Debt Conversion, Converted Instrument, Shares Issued	1,132,059
Debt Instrument, Face Amount					$ 13,200
Notes Payable					$ 15,000
Notes Payable Issued For Consulting Agreement [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate During Period			10.00%
Debt Instrument, Convertible, Conversion Price	$ 3.40		$ 3.40
[custom:BeneficialOwnershipLimit-0]			4.99%
Notes Payable, Current	$ 33,300			400
Debt Conversion, Converted Instrument, Amount				4,800
Debt Conversion, Converted Instrument, Shares Issued	1,627,440
Accrued Liabilities, Current	$ 5,500		$ 700
Notes Payable Issued For Consulting Agreement [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	472,059
Notes Payable Issued For Consulting Agreement [Member] | January 2021 [Member]
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 38,800
Debt Conversion, Converted Instrument, Shares Issued	11,413,322
Notes payable issued exchange for consulting service		$ 700
Accrued Liabilities, Current	$ 5,500			500
Notes Payable Issued For Consulting Agreement [Member] | Fiscal 2019 and 2020 [Member]
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 1,600
Adoption of ASU 2020-06 [Member] | During 2020 [Member]
Short-term Debt [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature			4,700
Debt Instrument, Unamortized Discount				$ 4,500
[custom:InterestExpenseDueAmortizationOfDebtDiscount-0]			200
Adoption of ASU 2020-06 [Member] | January 1, 2021 [Member]
Short-term Debt [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature			4,700
Debt Instrument, Unamortized Discount			$ 4,500

Line of Credit (Details Narrati

Line of Credit (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Nov. 08, 2010
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity			$ 300,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 800,000
Derivative, Fixed Interest Rate			2.00%
Long-term Line of Credit	$ 31,000	$ 31,000

Schedule of Derivative Liabilit

Schedule of Derivative Liabilities Assumptions (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 28, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 200	$ 138,000	$ 383,000
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield		1.26	0.36
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield		129	135
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (in years)		3 years 7 months 6 days	4 years 7 months 6 days
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield		0	0

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative Liability
Warrant exercised	2,826
Derivative liability	$ 30,000
Derivative, Gain on Derivative	$ 210,000
Derivative, Loss on Derivative		$ 230,000

Schedule of Warrant activity (D

Schedule of Warrant activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Warrants Outstanding,Beginning Balance	221,041	106,650
Weighted Average Exercise Price, Beginning Balance	$ 3.40	$ 3.40
Granted	5,192,250	382,353
Granted	$ 5.50	$ 3.40
Forfeited		(28,256)
Forfeited		$ 3.40
Exercised	(3,076,017)	(239,706)
Expired	$ 5.50
Warrants Outstanding, Ending Balance	2,337,274	221,041
Weighted Average Exercise Price, Ending Balance	$ 5.30	$ 3.40
Warrants Exercisable	2,337,274
Exercisable	$ 5.30

Schedule of Options Activity (D

Schedule of Options Activity (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Equity [Abstract]
Options outstanding, beginning | shares
Exercise Price of Warrants or Rights | $ / shares
Granted | shares	302,500
Granted | $ / shares	$ 3.05
Forfeited | shares
Forfeited | $ / shares
Exercised | shares
Exercised | $ / shares
Options outstanding, Ending | shares	302,500
Exercise Price of Warrants or Rights | $ / shares	$ 3.05
Options exercisable | shares	93,825
Options Exercisable | $ / shares	$ 3.05

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)	Feb. 16, 2021	Feb. 10, 2021	Jul. 31, 2020	Feb. 28, 2021	Jul. 28, 2020	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2021
Class of Stock [Line Items]
Common Stock, Shares Authorized						750,000,000	750,000,000
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Preferred Stock, Shares Authorized						15,000,000	15,000,000
Preferred stock, par value						$ 0.01	$ 0.01
Stockholders' Equity, Reverse Stock Split		1:17
Debt Conversion, Converted Instrument, Amount	$ 38,800,000
Debt Conversion, Converted Instrument, Shares Issued	11,413,322
Stock Issued During Period, Value, New Issues
Common stock conversion value							$ 1,700,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			323,529
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.40
Accrued Liabilities, Current						1,901,000	$ 1,296,000
Stock based compensation expense						$ 33,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						550,479
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value						$ 2,200,000
Cashless exercise of warrants						3,076,017	239,706
Shares issued upon conversion							511,879
Shares issued						32,061,989	5,218,122	187,500
Fair value adjustment of warrant							$ 2,246,000
Common Stock, Shares, Outstanding						32,061,989	5,218,122
Fair Value Adjustment of Warrants					$ 200,000	$ 138,000,000	$ 383,000,000
Class of warrant expire date			Jun. 19, 2025
Warrants Intrinsic Value						$ 0
Stock option granted						302,500
Stock options exercisable price						$ 3.05
Options outstanding intrinsic value						$ 0
Two Employees [Member]
Class of Stock [Line Items]
Stock based compensation expense						$ 250,700
Stock option granted						302,500
Stock options exercisable price						$ 3.05
Options expiration period						10 years
Fair value of options						$ 808,000
Fair value of stock option, per share						$ 2.67
Expected term						5 years 6 months
Expected volatility						129.00%
Interest rate						1.26%
Dividend yield						0.00%
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						3,076,017
Proceeds from Issuance of Warrants						$ 16,400,000
Consulting Agreements [Member]
Class of Stock [Line Items]
Preferred stock shares designated	2,850,090					1,060,853
Stock Issued During Period, Value, New Issues	$ 10,700,000					$ 6,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	1,934,817
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingNumberOfShares]	915,273
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	common stock vests over two years
Stock based compensation expense						$ 9,000,000
Vesting period						24 years
Shares cancelled				278,058
Share-based Payment Arrangement, Expense						$ 15,300,000
Research and Development Agreement [Member]
Class of Stock [Line Items]
Preferred stock shares designated						189,753
Stock Issued During Period, Value, New Issues						$ 1,400,000
Settlement Agreements [Member]
Class of Stock [Line Items]
Shares issued							262,353
Common Stock [Member]
Class of Stock [Line Items]
Preferred stock shares designated						692,000
Stock Issued During Period, Value, New Issues						$ 1,000
Fair value adjustment of warrant
Conversion of shares							512,000
Minimum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage						1.00%
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage						3.00%
IPO [Member]
Class of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	11,413,322
Preferred stock shares designated	4,945,000
Proceeds from Issuance Initial Public Offering	$ 24,700,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,192,250				58,824
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.50				$ 3.40
Warrant term	5 years
Convertible Notes Payable	$ 33,300,000
Accrued Liabilities, Current	$ 5,500,000
Debt Instrument, Convertible, Conversion Price	$ 3.40
Common Stock [Member]
Class of Stock [Line Items]
Preferred stock shares designated						11,085,703
Equity Method Investment, Ownership Percentage						97.10%
Stock Issued During Period, Value, New Issues						$ 37,700,000
Common Stock, Shares Subscribed but Unissued						327,298
Due to Related Parties						$ 1,100,000
Common stock conversion value						$ 1,100,000
Series J Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued						0	2,353,548
Preferred stock, shares outstanding						0	2,353,548
Conversion of shares				692,220
Series J Preferred Stocks [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage						9.99%
Debt Instrument, Convertible, Conversion Price						$ 3.40
Series C Preferred Stocks [Member]
Class of Stock [Line Items]
Preferred stock, par value						$ 0.01
Preferred stock, shares issued						96,230	96,230
Preferred stock, shares outstanding						96,230	96,230
Series K Preferred Stocks [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01
Preferred stock shares designated	115,000
Preferred stock, shares issued						0
Preferred stock, shares outstanding						0

Schedule Of Future Minimum Leas

Schedule Of Future Minimum Lease Payments (Details) $ in Thousands	Jan. 01, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 113
2023	117
2026 and thereafter	60
Total	$ 290

Schedule of Company_s Future Fi

Schedule of Company’s Future Financial Commitment (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 1,756
2023	1,293
2024	1,012
2025	377
2026 and thereafter
Total	$ 4,438

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Mar. 04, 2022USD ($)	Mar. 03, 2022USD ($)	Dec. 29, 2021USD ($)	Dec. 02, 2021USD ($)	Nov. 19, 2021ft²	Aug. 06, 2021USD ($)	Mar. 26, 2021USD ($)	Oct. 05, 2020	Mar. 31, 2021USD ($)	Dec. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Loss Contingencies [Line Items]
Project fees											$ 2,100,000
Initial payment			$ 191,527	$ 541,527
Periodic payment to be made											191,527
Final payment											192,470
Other Commitments, Description								On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At December 31, 2021, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $7.5 million was incurred at that date and an additional $5.5 million is in process during fiscal year 2022.
Received upfront payment											200,000
Annual maintanance fee											$ 100,000
Royalty fee percentage											0.04
Annual royalty payments									$ 250,000
Performance milestone payments									3,100,000		$ 3,100,000
Sales milestone payments									1		1,000,000
Gross sales									250,000,000		250,000,000
Sales revenue									5	$ 5
Cummulative gross sales									500,000,000	$ 500
Upfront license fee							$ 20,000
License maintenance fee, receivable											5,000
[custom:MaintananceFee]									$ 2
Aimmune Therapeutics Inc [Member]
Loss Contingencies [Line Items]
Area of Land | ft²					4,500
Lessee, Operating Sublease, Option to Extend					commencement date of January 1, 2022 and maturing on June 30, 2024
Minimum [Member]
Loss Contingencies [Line Items]
Annual royalty payments											250,000
[custom:NetSalesPercentage]									0.025
Maximum [Member]
Loss Contingencies [Line Items]
[custom:NetSalesPercentage]									0.05
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member]
Loss Contingencies [Line Items]
Commitment amount for services, total											13,000,000
Commitment cost incurred											7,500,000
Compensation cost expected to be incurred in future											$ 5,500,000
Sheffield Properties [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Expense						$ 100,000
Subsequent Event [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Expense	$ 425,000,000,000	$ 400,000

Schedule of Net Deferred Income

Schedule of Net Deferred Income Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal net operating loss carryforward	$ 58,167	$ 39,340
Stock based compensation and other items	7,622	4,779
Intellectual property	62,055	58,504
Patent amortization	4	4
Deferred tax assets before valuation	127,848	102,627
Valuation allowance	(127,848)	(102,627)
Net deferred income tax assets

Schedule of Income Tax Provisio

Schedule of Income Tax Provision (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	21.00%
State tax, net of federal benefit	9.00%	7.00%
Change in valuation allowance on net operating loss carryforwards	30.00%	28.00%
Effective income tax rate	0.00%	0.00%

Income Tax (Details Narrative)

Income Tax (Details Narrative) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 195
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Deferred Tax Assets Valuation Allowance, Percent	100.00%

Related Party Transaction (Deta

Related Party Transaction (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021
Related Party Transaction [Line Items]
Professional Fees	$ 1,100
Notes Payable, Related Parties, Current		$ 500
Accrued Liabilities, Current	1,296	$ 1,901
Consultant [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		10.00%
Accrued Liabilities, Current	$ 500	$ 0

Equity Compensation to Office_2

Equity Compensation to Officers, Board of Directors and Employees (Details Narrative) - USD ($) $ in Millions	Feb. 16, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, New Issues
Share-based Payment Arrangement, Noncash Expense		$ 33.9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		550,479
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		$ 2.2
Employment Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues	4,379,407
Stock Issued During Period, Value, New Issues	$ 18.6
Chief Executive Officer [Member] | Employment Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		10.00%
Chief Financial Officer [Member] | Employment Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		1.50%
Director [Member] | Employment Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description		Pursuant to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining
Director [Member] | Employment Agreements [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		1.00%
Director [Member] | Employment Agreements [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		1.25%
Officers and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Noncash Expense		$ 17.2
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		4,053,024
Vested shares		93,825
Share based compensation cancelled		278,058
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		338,883
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		$ 1.7

Internal Control Consideratio_2

Internal Control Considerations (Details Narrative) - USD ($) $ in Millions	1 Months Ended
	Jul. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Internal Control Considerations
[custom:ShortTermAdvance]	$ 2.6
Common Stock, Shares, Issued	187,500	32,061,989	5,218,122

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) $ in Millions	Mar. 04, 2022USD ($)	Mar. 03, 2022USD ($)	Feb. 11, 2022shares	Nov. 19, 2021ft²	Dec. 31, 2020shares
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued					511,879
Aimmune Therapeutics Inc [Member]
Subsequent Event [Line Items]
Area of Land | ft²				4,500
Lessee, Operating Sublease, Option to Extend				commencement date of January 1, 2022 and maturing on June 30, 2024
Subsequent Event [Member]
Subsequent Event [Line Items]
Litigation Settlement, Expense | $	$ 425,000	$ 0.4
Conversion of Stock, Shares Issued			60,855